Zentalis Pharmaceuticals, Inc.

Zentalis Pharmaceuticals, Inc. (ZNTL) priced its initial public offering on Apr 6, 2020 at $18.00 per share, raising $165.2M, and listed on Nasdaq Global Market. At the IPO price its market capitalization was about $621M. Morgan Stanley was lead-left underwriter, joined by Jefferies, Leerink Partners and Guggenheim. Latham & Watkins advised the company and Cooley advised the underwriters.

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company discovering and developing small molecule therapeutics aimed at fundamental biological pathways of cancers. It uses an Integrated Discovery Engine combining cancer biology and medicinal chemistry, initially focusing on validated oncology targets with large patient populations.

Status

IPO

Ticker

ZNTL

Exchange

Nasdaq Global Market

Priced

Apr 6, 2020

IPO price

$18.00

Raised

$165.2M

Market cap at IPO price

$621M

First filed

Mar 6, 2020

Underwriters

Morgan Stanley, Jefferies, Leerink Partners and Guggenheim

Company counsel

Latham & Watkins

Underwriters' counsel

Cooley

Sector

Biotech & pharma

Country / state

CA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.